You are here: Industry Insights > Primary Endpoint

News List

AstraZeneca’s Stage IV Lung Cancer Drug Misses Primary Endpoint americanpharmaceuticalreview
August 23, 2019
AstraZeneca has announced final overall survival (OS) results from the Phase III NEPTUNE trial, a randomized, open-label, multi-center, global trial of Imfinzi (durvalumab) in combination with tremelimumab ...
Farxiga Meets Primary Endpoint in Heart Failure Trial americanpharmaceuticalreview
August 21, 2019
AstraZeneca has announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of ...
Entresto Study Misses Primary Endpoint americanpharmaceuticalreview
August 02, 2019
Novartis announced topline results from the global Phase III PARAGON-HF study, investigating the safety and efficacy of sacubitril/valsartan versus the active comparator valsartan in HFpEF patients.
BMS’ Opdivo fails to meet primary endpoint in NSCLC pharmaceutical-technology
July 26, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients with first-line non-squamous non-small cell
Anifrolumab Trial Does Not Meet Primary Endpoint americanpharmaceuticalreview
September 03, 2018
AstraZeneca and MedImmune announced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE).
Carmelina Cardiovascular Outcome Trial met its Primary Endpoint americanpharmaceuticalreview
July 24, 2018
Carmelina met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Trajenta (linagliptin) demonstrating similar cardiovascular safety compared to placeb
New Phase 3 Data Shows Vedolizumab Met Primary Endpoint americanpharmaceuticalreview
July 24, 2018
Takeda announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerati
TECENTRIQ, COTELLIC Did Not Meet Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Genentech announced the Phase III IMblaze370 study evaluating the combination of TECENTRIQ (atezolizumab) and COTELLIC (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib.
Fasenra Does Not Meet Primary Endpoint in Severe COPD Study americanpharmaceuticalreview
May 18, 2018
AstraZeneca and MedImmune announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Lilly's Galcanezumab Meets Primary Endpoint americanpharmaceuticalreview
May 18, 2018
Eli Lilly and Company announced galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache,

Previous page 1 2 Next page